



GLOBAL WELLNESS
STRATEGIES

Q4 2021 INVESTOR
PRESENTATION

PRESENTATION DISCLAIMER

These materials have been prepared by Global Wellness Strategies Inc. solely for its own use and may not be reproduced, redistributed or passed on to any other person or published for any purpose. You agree to maintain absolute confidentiality regarding the information disclosed in these materials. Each person accepting these materials agrees to return them promptly upon request

No Representations or Warranties

Global Wellness Strategies Inc. does not make any representation or warranty express or implied as to the accuracy, completeness or correctness of the information contained herein and no reliance should be placed thereon. It is not the intention to provide a complete or comprehensive analysis of Global Wellness Strategies Inc.'s financial or business prospects. The information contained in these materials should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date these materials were prepared. This presentation contains information obtained from third parties, including but not limited to market data. Global Wellness Strategies Inc. believes such information to be accurate but has not independently verified such information. To the extent such information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by Global Wellness Strategies Inc. based on such representations are not accurate.

No Offering of Securities

This document does not constitute an offer or invitation to purchase or subscribe for any securities and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto. Any offer and sale of securities will be made only through formal offering documents that contain important information about risks, fees and expenses, and have been prepared in accordance with applicable law specifically for the purposes of making such offer and sale. No securities of Global Wellness Strategies Inc. may be offered or sold in Canada except in accordance with the Securities Act (British Columbia) or the United States except pursuant to an exception from the registration requirements of the Securities Act of 1933. No securities commission or similar authority in Canada has reviewed these materials. Neither the US Securities and Exchange Commission nor any US federal or state securities commission or regulatory authority has recommended or approved any investment or the accuracy or completeness of any of the information provided in this document.





WORKING TOGETHER TO BUILD A BETTER WORLD

Global Wellness Strategies is a prospect generator providing high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The present focus of the company is CBD, functional mushrooms, and psychedelic related product companies.

INVESTMENT HIGHLIGHTS

.....●.....



PUBLICLY TRADED GLOBALLY

CSE : GWS | OTCQB : PNNRF | FSE : O3X



EXPERIENCED MANAGEMENT TEAM

Over 100 years of experience in business, consulting, capital markets, corporate finance, and healthcare services.



WELLNESS FOCUSED

Diversified portfolio of companies that are disrupting the health and wellness industries with a focus on CBD, functional mushrooms and psychedelic therapies.



HIGH GROWTH VERTICALS

Building a portfolio that utilizes CBD, mushrooms and psychedelics for recreational and medical use.



MANAGEMENT

Meris Kott CEO, Director

Meris has been in international Investment Banking & Financial Consultancy with a focus on targeting companies for investment and acquisition purposes for large multinational corporations. Meris has continued providing global bridges for public companies for 25 years and she believes all companies should create global footprints. In 1990, she founded Polaris Partners that financed in excess of 500 Million USD. She has an economics degree from McGill University. She is a swimmer and credits her perseverance and business tenacity to her sports background.

Stephen Brohman CFO

Stephen is a principal at Donaldson Brohman Martin, CPA Inc. and has 10+ years of working experience in a variety of roles with public and private companies and is experienced in corporate finance.

Leah Kincaid KaleidoMyco

Leah is the visionary founder of KaleidoMyco. She is also the CEO of Intercontinental Hemp LLC. In the past six years, Leah has brought together an exceptional transnational team to execute her vision for the full potential of hemp as a product for health and well-being worldwide.

Dr. Robert Klein, DC Strategic Medical Advisor

Dr. Klein has been the chiropractor for Florida Atlantic University for 15 years and serves on the board of the Florida Chiropractic Association. Robert earned his doctorate from the National College of Chiropractic in Lombard, Illinois.

Lindsey Perry Jr. Director

Lindsey was born and raised in New England and relocated to south Florida from Nantucket in 2005. His family is credited as being one of the pioneering families to develop the Island of Nantucket as a vacation destination. Perry sold his business, the Tristram's Group Inc., to retire, he has continued investing in numerous private and public entities. Lindsey graduated from Bucknell University in 1977 with a bachelor of science degree majoring in accounting, and played collegiate hockey and golf for the NCAA Bucknell Bisons.

Mark Ireton Director

Mark is a banker by profession with over 30 years of experience in all areas of commercial mid-market lending. He is versed in both public and private transactions and divestitures in various sectors. Mark also sits on private and public boards.

Ashleigh Vogstad Director

Ashleigh is the founder and CEO of Transcends, a marketing agency that excels in branding and facilitates partnerships for technology companies and their global vendors like Microsoft.



OUR PORTFOLIO



BRAND PARTNER



SHANTI
THERAPEUTICS

*Pharmaceutical grade
psychedelic solutions to
solve unmet medical
needs in the field of
chronic pain.*

Assets being acquired from Cannvalate Pty Ltd. through their wholly owned subsidiary, Shanti Therapeutics include but are not limited to application patents, intellectual property, formulae, compounds, solutions, research, data, techniques, processes, brand names, trade names, trademarks.




PROBLEMS



- ▶ Chronic Pain has a huge psychosocial component (up to 50%) which is not addressed by existing analgesics.
- ▶ No psychedelic drugs to-date have been approved as analgesics.
- ▶ In developed nations like Australia, approximately 10% of the population have chronic pain and the financial impact of this in Australia in 2020 was \$144.10 billion.
- ▶ There are no clinics in Australia allowing prescribing of psychedelics for pain or psychedelic-assisted psychotherapy. Currently, under Australian law, psychedelic drugs can be prescribed under the Special Access Scheme B system. (SAS-B).

Shanti is planning to conduct a single center, phase II, randomised, single-dose, crossover study to determine the preliminary efficacy of Paracetamol and MDMA individually and in combination in healthy participants. The study will be conducted jointly with the Swinburne Institute of Technology in Melbourne, Australia.

PROJECT TIMELINE



BRAND PARTNER

KaleidoMyco is one of the world's first companies combining hemp extract, adaptogens and myco based ingredients to produce world-class, data-driven, science-based wellness products. It is dedicated to driving ground-breaking innovations in the production and delivery of myco-derived formulations. KaleidoMyco has a team of experts who are actively working to lay the foundation in the psilocybin space as more developments in regulation become available.



FUNCTIONAL MUSHROOMS

Cordyceps



This mushroom is known for being very stimulating — for both energy and the libido.

What are they?

Functional mushrooms are fungi that are recognized as having additional benefits such as supporting overall health and well-being beyond their nutritional components. Some of these benefits may include:

- Sharpening cognitive function
- Lowering stress levels
- Increase of libido, among many others


Reishi

This mushroom has been used to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue.



Chaga

This mushroom is an antioxidant powerhouse, making it an excellent contender for fighting free radicals and inflammation.





Functional Fizz

A proprietary blend of functional mushrooms and hemp extract delivered as a delicious effervescent added to water or your favorite drink.



One Shot

A power packed shot of a proprietary blend of functional mushrooms and hemp extract

BRAND PARTNER

Sunshine State Tea has developed a line of delicious caffeinated black tea and decaffeinated herbal tea plus either Hemp CBD or Vitamin D. Infused teas are changing how we nutritionally engineer our bodies and minds for optimal function and performance.





THE POWER IN A CUP OF TEA

Tea is a very powerful drink and it has been consumed for millennia and has numerous benefits to our overall well-being.

1 + 1 doesn't always = 2

The convergence of two beneficial organic compounds into one singular delicious drink creates something that is much more than either tea, Vitamin D, or Hemp CBD, on their own.

TEA AND OUR INFUSIONS

The global market for both Tea, Hemp CBD and Vitamin D are on the rise. While CBD production is well established in the U.S. Sunshine State is committed to producing tea domestically with its partners in Washington State.

GLOBAL MARKETS ²⁰¹⁸



52

Billion Dollar
Tea market



23.6

Billion Dollar
CBD market*



60

Tea farms
in the US



86

Million Dollar
CBD Infused
Drink Market*

*Source: Grand View Research, Inc.

*Source: Zenith Global





Black Teas - Caffeinated

- Coconut Thai
- Earl Grey
- Blackberry Leaf
- Fruit n' Flower



Herbal Teas – Decaffeinated

- Hibiscus Rose
- Tropic Fruit
- Mocha Chicory
- Citrus Greens



OUR TEAS



CAPITAL STRUCTURE

GLOBAL WELLNESS STRATEGIES INC. CSE : GWS | OTCQB : PNNRF | FSE : O3X

Common Shares Outstanding

22,266,906

Recent Stock Price

\$0.30

Market Capitalization

~\$6,680,000

Options Outstanding

478,750

Fully Diluted Shares Outstanding

22,745,656

DEAL TERMS

GLOBAL WELLNESS STRATEGIES INC. CSE : GWS | OTCQB : PNNRF | FSE : O3X

ISSUER	Global Wellness Strategies Inc.
ISSUE	Non-Brokered Private Placement of 16,666,666 UNITS. Each Unit consisting of one Common share (the "Shares") in the capital of the Company and one Share Purchase warrant exercisable for an additional Share for a period of 36 months at an exercise price of \$0.30.
AMOUNT	CAD \$3,000,000 (the "Offering").
ISSUE PRICE	CAD \$0.18 per UNIT
CLOSING DATE	The closing of the Offering is to occur on or before October 1, 2021, or such other date as may be agreed upon by the Company
HOLD PERIOD	The Offered Securities will be subject to a statutory hold period in the Jurisdictions for a period of four months and one day from the Closing Date.
USE OF PROCEEDS	To further the 100% acquisition of Cannvalate Pty Ltd subsidiary Shanti Therapeutics Pty Ltd based in Australia and their commencement of proof-of-concept clinical trial submissions, plus non-clinical studies for opening an IND (Investigational New Drug) File with the FDA. Funds will also be used for the establishment of a psychedelic prescribing clinic plus help to compensate the scientific executive team and for general and administrative expenses.



USE OF PROCEEDS

GLOBAL WELLNESS STRATEGIES INC.

CSE : GWS | OTCQB : PNNRF | FSE : O3X

Total POC Clinical trial fee (Inclusive of all product, staffing, ethics, research staff, University fees, patient recruitment fees, licenses, placebo manufacturing).	\$1,200,000 (\$550,000 R&D rebate) Net cost \$650,000
Toxicology - To be outsourced at ~\$300-400k each (2x tox studies)	\$600,000-800,000
FDA Regulatory Consultant for Pre-IND	\$180,000
CMC/ batch manufacturing	\$500,000
Brand Partner Products	\$300,000
General & Administrative Expenses	\$200,000
Total	~\$2,600,000



CONTACT:

MERIS KOTT, CEO

info@globalwellnessstrategies.com

GLOBAL WELLNESS
• STRATEGIES •